For example, repurposing of therapies targeting excitation–contraction coupling and Ca2+ homeostasis can be envisaged for CACNA1S or the SOCE pathway [70], or anti-oxidant modulators for PYROXD1-related myopathy. The gene discussed is PYROXD1; the disease is myopathy.